Lv7
4360 积分 2022-04-08 加入
Enhancing the bystander effect of antibody-drug conjugate by using a novel caspase-3 cleavable peptide linker to overcome tumor heterogeneity
6天前
已完结
In vivo antibody-selective conjugation technology for long-acting drugs
2个月前
已完结
Unveiling the molecular and immunological drivers of antibody–drug conjugates in cancer treatment
2个月前
已完结
Advanced Antibody–Drug Conjugates Design: Innovation in Linker Chemistry and Site‐Specific Conjugation Technologies
2个月前
已完结
Recent Advances in Peptide Linkers for Antibody-Drug Conjugates
2个月前
已完结
Risk Assessment and Control of N-Nitrosamines in Antibody–Drug Conjugates: Current Industry Practices
3个月前
已完结
Antibody–bottlebrush prodrug conjugates for targeted cancer therapy
3个月前
已完结
In vivo antibody-selective conjugation technology for long-acting drugs
3个月前
已完结
Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy
3个月前
已完结
Pharmacology and pharmacokinetics of antibody-drug conjugates, where do we stand?
3个月前
已完结
皖公网安备34019202002308
